what vyvanse does to the brain

Central Nervous System Effects of Lisdexamfetamine

Mechanism of Action: Prodrug Conversion and Monoamine Modulation

Lisdexamfetamine is a pharmacologically inactive prodrug. Following oral administration, it is converted to dextroamphetamine and l-lysine through enzymatic hydrolysis, primarily via red blood cells. Dextroamphetamine is a central nervous system stimulant that affects several neurotransmitter systems. Its primary action involves increasing the levels of dopamine and norepinephrine in the synaptic cleft. This is achieved through several mechanisms:

  • Inhibition of Reuptake Transporters: Dextroamphetamine binds to and inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing the reabsorption of these neurotransmitters from the synapse.
  • Reversal of Transporter Function: At higher concentrations, dextroamphetamine can reverse the function of DAT and NET, causing them to release dopamine and norepinephrine into the synapse.
  • Vesicular Monoamine Transporter 2 (VMAT2) Interaction: Dextroamphetamine enters presynaptic neurons and can displace dopamine and norepinephrine from storage vesicles (via VMAT2). This leads to increased cytosolic concentrations of these neurotransmitters, further promoting their release.

Neurotransmitter System Impact

Dopaminergic Effects

Increased dopamine signaling in the mesolimbic pathway is associated with the reinforcing and motivational effects. In the prefrontal cortex, dopamine enhancement can improve attention, working memory, and executive functions. Chronic exposure can lead to adaptations in dopamine receptor density and sensitivity.

Noradrenergic Effects

Norepinephrine affects arousal, vigilance, and attention. Increased norepinephrine signaling in the locus coeruleus enhances alertness and focus. Peripheral noradrenergic effects can contribute to cardiovascular changes.

Neuroanatomical Targets

  • Prefrontal Cortex: Influences executive functions, attention, and working memory.
  • Striatum (including Nucleus Accumbens): Mediates reward and motivation.
  • Locus Coeruleus: Regulates arousal and vigilance.
  • Hypothalamus: Affects appetite and sleep-wake cycles.

Potential Long-Term Neurological Adaptations

Chronic administration may lead to neuroadaptations, including changes in receptor expression, altered synaptic plasticity, and potential structural modifications. The long-term effects are still under investigation. Tolerance and dependence can develop with prolonged use, requiring higher doses to achieve the same effect. Abrupt cessation after prolonged use may result in withdrawal symptoms. Studies investigating long-term neurotoxicity have yielded mixed results, and further research is warranted.

Pharmacokinetics and Metabolism

Lisdexamfetamine is a prodrug that requires enzymatic conversion for activity. This conversion is relatively slow, leading to a gradual increase in dextroamphetamine levels. The half-life of dextroamphetamine is typically around 10-12 hours. Dextroamphetamine is primarily metabolized in the liver via CYP2D6 and other metabolic pathways. Genetic variations in CYP2D6 can affect the rate of metabolism and drug clearance.